Arvinas, Inc. (ARVN)
After hours:
| Previous close | 31.60 |
| Open | 31.73 |
| Bid | 32.34 x 100 |
| Ask | 32.40 x 100 |
| Day's range | 31.04 - 32.72 |
| 52-week range | 13.57 - 53.08 |
| Volume | |
| Avg. volume | 769,819 |
| Market cap | 2.211B |
| Beta (5Y monthly) | 1.89 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -6.62 |
| Earnings date | 03 May 2024 - 07 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 70.83 |
ZacksArvinas, Inc. (ARVN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Arvinas (ARVN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GlobeNewswireArvinas Appoints Randy Teel, Ph.D., as Chief Business Officer
NEW HAVEN, Conn., April 24, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the appointment of Randy Teel, Ph.D., to the newly created role of Chief Business Officer. Dr. Teel currently serves as Arvinas’ interim Chief Financial Officer and Treasurer, and in his new role, he will remain a member of the Executive Committee reporting to Chairperson, President and Chief
ZacksNovartis (NVS) Inks Deal for ARVN's Prostate Cancer Candidate
Novartis (NVS) enters into a license deal with Arvinas, Inc. (ARVN) for the worldwide development and commercialization of cancer candidate ARV-766. Shares of ARVN rise on the news.
